AstraZeneca (MEX:AZNN) Change In Payables And Accrued Expense : MXN0 Mil (TTM As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is AstraZeneca Change In Payables And Accrued Expense?

AstraZeneca's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was MXN0 Mil. It means AstraZeneca's Accounts Payable & Accrued Expense stayed the same from Dec. 2024 to Mar. 2025 .

AstraZeneca's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was MXN0 Mil. It means AstraZeneca's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Dec. 2024 .

AstraZeneca Change In Payables And Accrued Expense Historical Data

The historical data trend for AstraZeneca's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Change In Payables And Accrued Expense Chart

AstraZeneca Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

AstraZeneca Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

AstraZeneca Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN0 Mil.

AstraZeneca Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (MEX:AZNN) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

AZNCF:USA AZN:USA AZN:Sweden AZN1:Mexico AZNl:UK AZN:UK ZEGA:Germany ZEG:Germany ZEG:Germany ZEG:Germany ZEGA:Germany ZEG:Germany A1ZN34:Brazil AZNA:Austria AZN:Argentina

Address

1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA

Website

https://www.astrazeneca.com

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines